Sight Sciences (SGHT) Short term Debt (2023 - 2026)
Sight Sciences' quarterly Short term Debt came in at $3.8 million in Q1 2026, up 71.11% quarter-over-quarter from $2.2 million in Q4 2023.
Sight Sciences has reported Short term Debt for 2 years, with the latest figure at $3.8 million in Q1 2026.
- For the quarter ending Q1 2026, Short term Debt changed N/A year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (changed N/A YoY), and the FY2023 full-year result was $2.2 million, changed N/A from the prior year.
- Short term Debt for Q1 2026 stood at $3.8 million, up from $2.2 million in the prior quarter.
- The five-year high for Short term Debt was $3.8 million in Q1 2026, with the low at $2.2 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Sight Sciences | 247.60 Mn | 162.64 Mn | 16.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.80 Mn |
| Dec 31, 2023 | 2.22 Mn |